Tellus Therapeutics
PrivateLast Round
Series A
Dec 13, 2022
Total Funding Raised
$38.37M
Company Overview
Tellus Therapeutics operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series A round in December 2022.
Tellus Therapeutics is a biopharmaceutical company that develops novel small-molecule therapies for newborns in neonatal intensive care units, specifically targeting the repair of white matter brain injury in premature infants.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tellus Therapeutics Comparables
Compare Tellus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deck Therapeutics | 82% | |
| ReAlta Life Sciences | 78% | |
| AyuVis Research | 71% |
For institutional investors. Book with your work email.
Tellus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 13, 2022 | ||||
| Seed | May 12, 2021 | ||||
| Grant | Dec 7, 2020 | ||||
| Grant | Dec 10, 2019 | ||||
| Grant | Oct 24, 2019 | ||||
Convertible Debt | Jan 31, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tellus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Perceptive Advisors | Series A |
| Xontogeny | Seed, Series A |
| Duke Clinical & Translational Science Institute | Grant |
| MassChallenge Israel | Grant |
| North Carolina Biotechnology Center | Grant |
| National Institute of Neurological Disorders and Stroke | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors increased 60% MoM.
For institutional investors. Book with your work email.
Tellus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tellus Therapeutics's valuation, stock price, and market status.
Is Tellus Therapeutics a public or private company?
Tellus Therapeutics is a private company.
What is the current stock price of Tellus Therapeutics?
Tellus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tellus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tellus Therapeutics worth (valuation)?
Valuation information for Tellus Therapeutics is not publicly available.
Can I buy Tellus Therapeutics stock?
Tellus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tellus Therapeutics's last funding round?
Tellus Therapeutics's most recent funding round was Series A on December 13, 2022.
Who are the main investors in Tellus Therapeutics?
Key investors in Tellus Therapeutics include Perceptive Advisors, Xontogeny.
Will Tellus Therapeutics IPO soon?
No public IPO plans have been announced for Tellus Therapeutics.
How can I track Tellus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tellus Therapeutics's shares on secondary markets.